Novel targets for ischemia reperfusion injury therapy in the liver

Ling LI; Binyao Chen; Huijia Zhao; Zhipeng Fan; Gongpeng Sun; Li Dong; Jiang Yue; Qifa YE

Return

Novel targets for ischemia reperfusion injury therapy in the liver

VernacularTitle: 肝脏缺血再灌注损伤的基因干预新靶点
Author: Ling LI ^{1
,

2
,

3
,

4} ; Binyao CHEN ^{1
,

2
,

3
,

4} ; Huijia ZHAO ^{1
,

2
,

3
,

4} ; Zhipeng FAN ^{1
,

2
,

3
,

4} ; Gongpeng SUN ^{1
,

2
,

3
,

4} ; Li DONG ^{1
,

2
,

3
,

4} ; Jiang YUE ⁵ ; Qifa YE ^{1
,

2
,

3
,

4}
Author Information

1. Zhongnan Hospital of Wuhan University
2. Institute of Hepatobiliary Diseases of Wuhan University
3. Transplant Center of Wuhan University
4. Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan 430071, China
5. Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, China
Publication Type:Review
Keywords: Reperfusion injury; Liver; Noncoding RNA; Therapy
From: Chinese Journal of Hepatobiliary Surgery 2019;25(12):948-951
CountryChina
Language:Chinese
Abstract: Liver ischemia-reperfusion injury (IRI) is a major complication of hemorrhagic shock, liver transplantation, and other liver surgeries. It’s important to study the targets towards liver IRI for preventing and mitigating the clinical renal injury. It has been reported that the peroxisome proliferator activated receptor gamma (PPARγ) protects the liver against IRI by targeting family with sequence similarity 3 member A (FAM3A). At the meantime, noncoding RNAs, including lncRNAs and miRNAs, have also been reported to play important roles on the process of hepatic IRI. This review briefly discussed the roles and mechanisms of PPARγ, FAM3A and noncoding RNAs in liver IRI, to find potential targets of gene therapy, aiming to prevent and mitigate the liver IRI as well as to improve postoperative liver function.